Skip to main content

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Onyx Pharmaceuticals



) pushed the Drugs industry higher today making it today's featured drugs winner. The industry as a whole closed the day up 1.1%. By the end of trading, Onyx Pharmaceuticals rose $6.53 (5.6%) to $123.49 on heavy volume. Throughout the day, 23,185,420 shares of Onyx Pharmaceuticals exchanged hands as compared to its average daily volume of 2,335,500 shares. The stock ranged in a price between $123.40-$123.70 after having opened the day at $123.65 as compared to the previous trading day's close of $116.96. Other companies within the Drugs industry that increased today were:

GW Pharmaceuticals PLC ADR



), up 18.8%,

Accelerate Diagnostics



), up 15.2%,

Biocryst Pharmaceuticals



Scroll to Continue

TheStreet Recommends

), up 13.7% and

Ambit Biosciences



), up 12.2%.

Onyx Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development and commercialization of therapies that target the molecular mechanisms that cause cancer in the United States and internationally. Onyx Pharmaceuticals has a market cap of $8.6 billion and is part of the health care sector. Shares are up 55.7% year to date as of the close of trading on Friday. Currently there are 6 analysts that rate Onyx Pharmaceuticals a buy, no analysts rate it a sell, and 6 rate it a hold.

TheStreet Ratings rates Onyx Pharmaceuticals as a


. The company's strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures and good cash flow from operations. However, as a counter to these strengths, we find that the company's return on equity has been disappointing.

On the negative front,

Mast Therapeutics



), down 40.6%,

Rigel Pharmaceuticals



), down 13.5%,

ANI Pharmaceuticals



), down 9.1% and

Biosante Pharmaceuticals



), down 9.1% , were all laggards within the drugs industry with




) being today's drugs industry laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the drugs industry could consider

SPDR S&P Pharmaceuticals ETF



) while those bearish on the drugs industry could consider

ProShares UltraShort Nasdaq Biotech




3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.